Hetero announces approval and launch of Movfor (Molnupiravir 200 mg) to treat high-risk adult patients with COVID-19

Hetero, a globally renowned vertically integrated pharmaceutical organization announced today that the Drug Controller General of India (DCGI) has granted it permission for manufacture and marketing of Molnupiravir capsules 200 mg (Movfor). Molnupiravir, an investigational oral antiviral, is indicated for restricted emergency use in India to treat adult patients with COVID-19 and with SpO2 93% and who have high risk of progression of the disease.

Hetero’s Movfor will be made available in a 40 capsule pack (200 mg per capsule) and will be marketed by its associate company ‘Hetero Healthcare’ in India with the support of its strong distribution network across the country.

Dr. B. Partha Saradhi Reddy, Chairman, Hetero Group of Companies, said: “This approval consolidates India’s efforts to address the world’s greatest health threats, i.e., COVID-19. Improving access to critical medicines will always remain the highest of priorities to us.”

Under the aegis of ‘Make in India’ campaign, commercial production of ‘Movfor’ will be undertaken at Hetero’s world-class facilities in Telangana and Himachal Pradesh, where it is ensured to meet highest quality standards.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button